Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
raygent.com
  • Emerging Biomarker Face-Off: BGMD Vs VRML 0 comments
    Jul 6, 2012 1:43 PM

    Vermillion Stock Outperforms BG Medicine Since April 3

    On 4/3/12 we posted the biomarker challenge featuring two emerging public companies that have approved diagnostic products. In a few weeks we will have Q2 financial data on these two companies BG Medicine (NASDAQ:BGMD) and Vermillion (NASDAQ:VRML). Here is a comparison over 90 days.

    • VRML stock is up 7% while BGMD stock is down 7.7%.
    • No significant changes were made in product revenue forecasts for either Company.
    • VRML shows more active trading with an average of 367k per day compared to 75k for BGMD,but VRML shows greater volatility.
    • VRML on June 15 presented a Poster on a new Peripheral Artery Disease biomarker currently in development.
    • BGMD on June 18 announced the availability of their galectin-3 diagnostic test through Atherotec Diagnostic Lab.

    We will provide additional information on these and other diagnostic companies as we cover the AACC Meeting in Los Angeles on July 16. We will look for personalized medicine trends that could impact diagnostic companies such as Qiagen (NASDAQ:QGEN), Response Genetics (NASDAQ:RGDX), Sequenom (NASDAQ:SQNM) as well as major genomic tools companies like Life Technologies (NASDAQ:LIFE) and Illumina (NASDAQ:ILMN).

           
    Company BGMedicine Vermillion  
      BGMD VRML  
    Price 4/3/12 $7 $2  
    7/6/12 6.46 2.14  
    Market Cap$M $139.40 $30.10  
      129 31.8  
    Cash Bal.$M 28 22  
      28.5 19.8  
    Book Value 24.7 10.3  
           
    Retain.Earn$M -108.6 -316  
      121 318.1  
    Rev Est 2012$M 3.2M 2.81M  
           
    EPS Est 2012 ($1.25) ($0.94)  
      ($1.40) ($0.77)  
    Lead Product Galectin-3 OVA1  
    Disease focus Cardiovascular Ovarian cancer  
           

    Disclosure: I am long ILMN, RGDX.

Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.